Glutathione

Introduction

Glutathione (GSH) is a ubiquitous endogenous tripeptide — γ-glutamyl-cysteinyl-glycine — synthesized in the cytosol of nearly every cell. It is the principal intracellular non-protein thiol antioxidant and a key substrate for phase II hepatic conjugation. Exogenous glutathione is used clinically (parenterally) in acetaminophen toxicity protocols via its precursor N-acetylcysteine; standalone glutathione is investigational in many other contexts.

Mechanism of Action

Glutathione neutralizes reactive oxygen species directly via its reactive thiol group and serves as a substrate for glutathione peroxidase and glutathione-S-transferase enzyme families. The reduced (GSH) form is regenerated from the oxidized (GSSG) form by glutathione reductase. The GSH/GSSG ratio is a recognized marker of cellular redox status.

Research Indications

Hepatic detoxification support, oxidative-stress conditions, idiopathic Parkinsonian symptoms (small studies), and adjunctive skin protocols (controversial; not approved).

Reconstitution

Typical 600 mg lyophilized vial: add 6 mL of bacteriostatic water (or sterile saline for IV use), swirl gently. Final concentration 100 mg/mL. A 1200 mg vial reconstituted with 6 mL yields 200 mg/mL.

Dosing Protocol (research literature)

Route drives dose. IV push: 600–2000 mg over 10–15 minutes, 2–3 times per week, in oxidative-stress and Parkinsonian protocols. IM/SC: 200–600 mg, 2–3 times per week. Nebulized inhalation: 200–600 mg in saline, daily to weekly. Oral liposomal: 500–1000 mg daily (poor bioavailability vs. parenteral routes). Cycle length 8–16 weeks with reassessment.

Administration

IV push slowly over 10–15 minutes (rapid push associated with flushing/nausea). IM into deltoid or gluteal muscle. SC into abdominal fat. Nebulized via standard compressor nebulizer.

Storage & Handling

Lyophilized: refrigerate (2–8°C); protect from light. Reconstituted: refrigerate; stable approximately 7–14 days — glutathione oxidizes readily once in solution. Discard if the solution turns yellow or develops particulate.

Side Effects

Generally well-tolerated. Rare hypersensitivity reactions reported with parenteral administration. Sulfurous body odor at higher doses.

Contraindications

Pregnancy and lactation without clinician supervision. Sulfa hypersensitivity (rare cross-reactivity). The skin-lightening indication carries case-report safety signals (Stevens-Johnson, thyroid dysfunction) warranting particular caution.

Monitoring

Baseline liver function tests, CBC, and a clinically relevant oxidative-stress instrument where supported. Re-measure at 8 and 16 weeks if used in chronic protocols.

Disclaimer

This article is for informational and research-reference purposes only. Nothing in this document constitutes medical advice, a prescription, or a recommendation from a physician. The reconstitution, dosing, and protocol information above reflects ranges commonly cited in published research and clinician-directed protocols — it is provided as reference material only, not as instructions, an endorsement of off-label use, or a substitute for individualized medical evaluation.

Customers should do their own research and consult their own physician before considering any peptide protocol. Whether a given compound is appropriate for an individual — and at what dose, for what duration, and alongside what monitoring — is a decision that only a licensed clinician with knowledge of that individual's medical history, current medications, and conditions can make.

The platform and the author make no claim that any compound described here is safe, effective, or appropriate for any particular person or purpose, and accept no responsibility for outcomes arising from self-directed use of the information.